Thrombospondin 1 enhances systemic inflammation and disease severity in acute-on-chronic liver failure
Background The key role of thrombospondin 1 (THBS1) in the pathogenesis of acute-on-chronic liver failure (ACLF) is unclear. Here, we present a transcriptome approach to evaluate THBS1 as a potential biomarker in ACLF disease pathogenesis. Methods Biobanked peripheral blood mononuclear cells (PBMCs)...
Saved in:
| Published in | BMC medicine Vol. 22; no. 1; pp. 95 - 17 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
05.03.2024
BioMed Central Ltd BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1741-7015 1741-7015 |
| DOI | 10.1186/s12916-024-03318-x |
Cover
| Abstract | Background
The key role of thrombospondin 1 (THBS1) in the pathogenesis of acute-on-chronic liver failure (ACLF) is unclear. Here, we present a transcriptome approach to evaluate THBS1 as a potential biomarker in ACLF disease pathogenesis.
Methods
Biobanked peripheral blood mononuclear cells (PBMCs) from 330 subjects with hepatitis B virus (HBV)-related etiologies, including HBV-ACLF, liver cirrhosis (LC), and chronic hepatitis B (CHB), and normal controls (NC) randomly selected from the Chinese Group on the Study of Severe Hepatitis B (COSSH) prospective multicenter cohort underwent transcriptome analyses (ACLF = 20; LC = 10; CHB = 10; NC = 15); the findings were externally validated in participants from COSSH cohort, an ACLF rat model and hepatocyte-specific THBS1 knockout mice.
Results
THBS1
was the top significantly differentially expressed gene in the PBMC transcriptome, with the most significant upregulation in ACLF, and quantitative polymerase chain reaction (ACLF = 110; LC = 60; CHB = 60; NC = 45) was used to verify that
THBS1
expression corresponded to ACLF disease severity outcome, including inflammation and hepatocellular apoptosis. THBS1 showed good predictive ability for ACLF short-term mortality, with an area under the receiver operating characteristic curve (AUROC) of 0.8438 and 0.7778 at 28 and 90 days, respectively. Enzyme-linked immunosorbent assay validation of the plasma THBS1 using an expanded COSSH cohort subjects (ACLF = 198; LC = 50; CHB = 50; NC = 50) showed significant correlation between THBS1 with ALT and γ-GT (
P
= 0.01), and offered a similarly good prognostication predictive ability (AUROC = 0.7445 and 0.7175) at 28 and 90 days, respectively. ACLF patients with high-risk short-term mortality were identified based on plasma THBS1 optimal cut-off value (< 28 µg/ml). External validation in ACLF rat serum and livers confirmed the functional association between THBS1, the immune response and hepatocellular apoptosis. Hepatocyte-specific THBS1 knockout improved mouse survival, significantly repressed major inflammatory cytokines, enhanced the expression of several anti-inflammatory mediators and impeded hepatocellular apoptosis.
Conclusions
THBS1 might be an ACLF disease development-related biomarker, promoting inflammatory responses and hepatocellular apoptosis, that could provide clinicians with a new molecular target for improving diagnostic and therapeutic strategies.
Graphical Abstract |
|---|---|
| AbstractList | Background The key role of thrombospondin 1 (THBS1) in the pathogenesis of acute-on-chronic liver failure (ACLF) is unclear. Here, we present a transcriptome approach to evaluate THBS1 as a potential biomarker in ACLF disease pathogenesis. Methods Biobanked peripheral blood mononuclear cells (PBMCs) from 330 subjects with hepatitis B virus (HBV)-related etiologies, including HBV-ACLF, liver cirrhosis (LC), and chronic hepatitis B (CHB), and normal controls (NC) randomly selected from the Chinese Group on the Study of Severe Hepatitis B (COSSH) prospective multicenter cohort underwent transcriptome analyses (ACLF = 20; LC = 10; CHB = 10; NC = 15); the findings were externally validated in participants from COSSH cohort, an ACLF rat model and hepatocyte-specific THBS1 knockout mice. Results THBS1 was the top significantly differentially expressed gene in the PBMC transcriptome, with the most significant upregulation in ACLF, and quantitative polymerase chain reaction (ACLF = 110; LC = 60; CHB = 60; NC = 45) was used to verify that THBS1 expression corresponded to ACLF disease severity outcome, including inflammation and hepatocellular apoptosis. THBS1 showed good predictive ability for ACLF short-term mortality, with an area under the receiver operating characteristic curve (AUROC) of 0.8438 and 0.7778 at 28 and 90 days, respectively. Enzyme-linked immunosorbent assay validation of the plasma THBS1 using an expanded COSSH cohort subjects (ACLF = 198; LC = 50; CHB = 50; NC = 50) showed significant correlation between THBS1 with ALT and [gamma]-GT (P = 0.01), and offered a similarly good prognostication predictive ability (AUROC = 0.7445 and 0.7175) at 28 and 90 days, respectively. ACLF patients with high-risk short-term mortality were identified based on plasma THBS1 optimal cut-off value (< 28 [micro]g/ml). External validation in ACLF rat serum and livers confirmed the functional association between THBS1, the immune response and hepatocellular apoptosis. Hepatocyte-specific THBS1 knockout improved mouse survival, significantly repressed major inflammatory cytokines, enhanced the expression of several anti-inflammatory mediators and impeded hepatocellular apoptosis. Conclusions THBS1 might be an ACLF disease development-related biomarker, promoting inflammatory responses and hepatocellular apoptosis, that could provide clinicians with a new molecular target for improving diagnostic and therapeutic strategies. Graphical Keywords: Acute-on-chronic liver failure, Thrombospondin 1, Immune-metabolism disorder, Severity prediction, Inflammatory response, Hepatocellular apoptosis The key role of thrombospondin 1 (THBS1) in the pathogenesis of acute-on-chronic liver failure (ACLF) is unclear. Here, we present a transcriptome approach to evaluate THBS1 as a potential biomarker in ACLF disease pathogenesis. Biobanked peripheral blood mononuclear cells (PBMCs) from 330 subjects with hepatitis B virus (HBV)-related etiologies, including HBV-ACLF, liver cirrhosis (LC), and chronic hepatitis B (CHB), and normal controls (NC) randomly selected from the Chinese Group on the Study of Severe Hepatitis B (COSSH) prospective multicenter cohort underwent transcriptome analyses (ACLF = 20; LC = 10; CHB = 10; NC = 15); the findings were externally validated in participants from COSSH cohort, an ACLF rat model and hepatocyte-specific THBS1 knockout mice. THBS1 was the top significantly differentially expressed gene in the PBMC transcriptome, with the most significant upregulation in ACLF, and quantitative polymerase chain reaction (ACLF = 110; LC = 60; CHB = 60; NC = 45) was used to verify that THBS1 expression corresponded to ACLF disease severity outcome, including inflammation and hepatocellular apoptosis. THBS1 showed good predictive ability for ACLF short-term mortality, with an area under the receiver operating characteristic curve (AUROC) of 0.8438 and 0.7778 at 28 and 90 days, respectively. Enzyme-linked immunosorbent assay validation of the plasma THBS1 using an expanded COSSH cohort subjects (ACLF = 198; LC = 50; CHB = 50; NC = 50) showed significant correlation between THBS1 with ALT and γ-GT (P = 0.01), and offered a similarly good prognostication predictive ability (AUROC = 0.7445 and 0.7175) at 28 and 90 days, respectively. ACLF patients with high-risk short-term mortality were identified based on plasma THBS1 optimal cut-off value (< 28 µg/ml). External validation in ACLF rat serum and livers confirmed the functional association between THBS1, the immune response and hepatocellular apoptosis. Hepatocyte-specific THBS1 knockout improved mouse survival, significantly repressed major inflammatory cytokines, enhanced the expression of several anti-inflammatory mediators and impeded hepatocellular apoptosis. THBS1 might be an ACLF disease development-related biomarker, promoting inflammatory responses and hepatocellular apoptosis, that could provide clinicians with a new molecular target for improving diagnostic and therapeutic strategies. The key role of thrombospondin 1 (THBS1) in the pathogenesis of acute-on-chronic liver failure (ACLF) is unclear. Here, we present a transcriptome approach to evaluate THBS1 as a potential biomarker in ACLF disease pathogenesis.BACKGROUNDThe key role of thrombospondin 1 (THBS1) in the pathogenesis of acute-on-chronic liver failure (ACLF) is unclear. Here, we present a transcriptome approach to evaluate THBS1 as a potential biomarker in ACLF disease pathogenesis.Biobanked peripheral blood mononuclear cells (PBMCs) from 330 subjects with hepatitis B virus (HBV)-related etiologies, including HBV-ACLF, liver cirrhosis (LC), and chronic hepatitis B (CHB), and normal controls (NC) randomly selected from the Chinese Group on the Study of Severe Hepatitis B (COSSH) prospective multicenter cohort underwent transcriptome analyses (ACLF = 20; LC = 10; CHB = 10; NC = 15); the findings were externally validated in participants from COSSH cohort, an ACLF rat model and hepatocyte-specific THBS1 knockout mice.METHODSBiobanked peripheral blood mononuclear cells (PBMCs) from 330 subjects with hepatitis B virus (HBV)-related etiologies, including HBV-ACLF, liver cirrhosis (LC), and chronic hepatitis B (CHB), and normal controls (NC) randomly selected from the Chinese Group on the Study of Severe Hepatitis B (COSSH) prospective multicenter cohort underwent transcriptome analyses (ACLF = 20; LC = 10; CHB = 10; NC = 15); the findings were externally validated in participants from COSSH cohort, an ACLF rat model and hepatocyte-specific THBS1 knockout mice.THBS1 was the top significantly differentially expressed gene in the PBMC transcriptome, with the most significant upregulation in ACLF, and quantitative polymerase chain reaction (ACLF = 110; LC = 60; CHB = 60; NC = 45) was used to verify that THBS1 expression corresponded to ACLF disease severity outcome, including inflammation and hepatocellular apoptosis. THBS1 showed good predictive ability for ACLF short-term mortality, with an area under the receiver operating characteristic curve (AUROC) of 0.8438 and 0.7778 at 28 and 90 days, respectively. Enzyme-linked immunosorbent assay validation of the plasma THBS1 using an expanded COSSH cohort subjects (ACLF = 198; LC = 50; CHB = 50; NC = 50) showed significant correlation between THBS1 with ALT and γ-GT (P = 0.01), and offered a similarly good prognostication predictive ability (AUROC = 0.7445 and 0.7175) at 28 and 90 days, respectively. ACLF patients with high-risk short-term mortality were identified based on plasma THBS1 optimal cut-off value (< 28 µg/ml). External validation in ACLF rat serum and livers confirmed the functional association between THBS1, the immune response and hepatocellular apoptosis. Hepatocyte-specific THBS1 knockout improved mouse survival, significantly repressed major inflammatory cytokines, enhanced the expression of several anti-inflammatory mediators and impeded hepatocellular apoptosis.RESULTSTHBS1 was the top significantly differentially expressed gene in the PBMC transcriptome, with the most significant upregulation in ACLF, and quantitative polymerase chain reaction (ACLF = 110; LC = 60; CHB = 60; NC = 45) was used to verify that THBS1 expression corresponded to ACLF disease severity outcome, including inflammation and hepatocellular apoptosis. THBS1 showed good predictive ability for ACLF short-term mortality, with an area under the receiver operating characteristic curve (AUROC) of 0.8438 and 0.7778 at 28 and 90 days, respectively. Enzyme-linked immunosorbent assay validation of the plasma THBS1 using an expanded COSSH cohort subjects (ACLF = 198; LC = 50; CHB = 50; NC = 50) showed significant correlation between THBS1 with ALT and γ-GT (P = 0.01), and offered a similarly good prognostication predictive ability (AUROC = 0.7445 and 0.7175) at 28 and 90 days, respectively. ACLF patients with high-risk short-term mortality were identified based on plasma THBS1 optimal cut-off value (< 28 µg/ml). External validation in ACLF rat serum and livers confirmed the functional association between THBS1, the immune response and hepatocellular apoptosis. Hepatocyte-specific THBS1 knockout improved mouse survival, significantly repressed major inflammatory cytokines, enhanced the expression of several anti-inflammatory mediators and impeded hepatocellular apoptosis.THBS1 might be an ACLF disease development-related biomarker, promoting inflammatory responses and hepatocellular apoptosis, that could provide clinicians with a new molecular target for improving diagnostic and therapeutic strategies.CONCLUSIONSTHBS1 might be an ACLF disease development-related biomarker, promoting inflammatory responses and hepatocellular apoptosis, that could provide clinicians with a new molecular target for improving diagnostic and therapeutic strategies. The key role of thrombospondin 1 (THBS1) in the pathogenesis of acute-on-chronic liver failure (ACLF) is unclear. Here, we present a transcriptome approach to evaluate THBS1 as a potential biomarker in ACLF disease pathogenesis. Biobanked peripheral blood mononuclear cells (PBMCs) from 330 subjects with hepatitis B virus (HBV)-related etiologies, including HBV-ACLF, liver cirrhosis (LC), and chronic hepatitis B (CHB), and normal controls (NC) randomly selected from the Chinese Group on the Study of Severe Hepatitis B (COSSH) prospective multicenter cohort underwent transcriptome analyses (ACLF = 20; LC = 10; CHB = 10; NC = 15); the findings were externally validated in participants from COSSH cohort, an ACLF rat model and hepatocyte-specific THBS1 knockout mice. THBS1 was the top significantly differentially expressed gene in the PBMC transcriptome, with the most significant upregulation in ACLF, and quantitative polymerase chain reaction (ACLF = 110; LC = 60; CHB = 60; NC = 45) was used to verify that THBS1 expression corresponded to ACLF disease severity outcome, including inflammation and hepatocellular apoptosis. THBS1 showed good predictive ability for ACLF short-term mortality, with an area under the receiver operating characteristic curve (AUROC) of 0.8438 and 0.7778 at 28 and 90 days, respectively. Enzyme-linked immunosorbent assay validation of the plasma THBS1 using an expanded COSSH cohort subjects (ACLF = 198; LC = 50; CHB = 50; NC = 50) showed significant correlation between THBS1 with ALT and [gamma]-GT (P = 0.01), and offered a similarly good prognostication predictive ability (AUROC = 0.7445 and 0.7175) at 28 and 90 days, respectively. ACLF patients with high-risk short-term mortality were identified based on plasma THBS1 optimal cut-off value (< 28 [micro]g/ml). External validation in ACLF rat serum and livers confirmed the functional association between THBS1, the immune response and hepatocellular apoptosis. Hepatocyte-specific THBS1 knockout improved mouse survival, significantly repressed major inflammatory cytokines, enhanced the expression of several anti-inflammatory mediators and impeded hepatocellular apoptosis. THBS1 might be an ACLF disease development-related biomarker, promoting inflammatory responses and hepatocellular apoptosis, that could provide clinicians with a new molecular target for improving diagnostic and therapeutic strategies. Abstract Background The key role of thrombospondin 1 (THBS1) in the pathogenesis of acute-on-chronic liver failure (ACLF) is unclear. Here, we present a transcriptome approach to evaluate THBS1 as a potential biomarker in ACLF disease pathogenesis. Methods Biobanked peripheral blood mononuclear cells (PBMCs) from 330 subjects with hepatitis B virus (HBV)-related etiologies, including HBV-ACLF, liver cirrhosis (LC), and chronic hepatitis B (CHB), and normal controls (NC) randomly selected from the Chinese Group on the Study of Severe Hepatitis B (COSSH) prospective multicenter cohort underwent transcriptome analyses (ACLF = 20; LC = 10; CHB = 10; NC = 15); the findings were externally validated in participants from COSSH cohort, an ACLF rat model and hepatocyte-specific THBS1 knockout mice. Results THBS1 was the top significantly differentially expressed gene in the PBMC transcriptome, with the most significant upregulation in ACLF, and quantitative polymerase chain reaction (ACLF = 110; LC = 60; CHB = 60; NC = 45) was used to verify that THBS1 expression corresponded to ACLF disease severity outcome, including inflammation and hepatocellular apoptosis. THBS1 showed good predictive ability for ACLF short-term mortality, with an area under the receiver operating characteristic curve (AUROC) of 0.8438 and 0.7778 at 28 and 90 days, respectively. Enzyme-linked immunosorbent assay validation of the plasma THBS1 using an expanded COSSH cohort subjects (ACLF = 198; LC = 50; CHB = 50; NC = 50) showed significant correlation between THBS1 with ALT and γ-GT (P = 0.01), and offered a similarly good prognostication predictive ability (AUROC = 0.7445 and 0.7175) at 28 and 90 days, respectively. ACLF patients with high-risk short-term mortality were identified based on plasma THBS1 optimal cut-off value (< 28 µg/ml). External validation in ACLF rat serum and livers confirmed the functional association between THBS1, the immune response and hepatocellular apoptosis. Hepatocyte-specific THBS1 knockout improved mouse survival, significantly repressed major inflammatory cytokines, enhanced the expression of several anti-inflammatory mediators and impeded hepatocellular apoptosis. Conclusions THBS1 might be an ACLF disease development-related biomarker, promoting inflammatory responses and hepatocellular apoptosis, that could provide clinicians with a new molecular target for improving diagnostic and therapeutic strategies. Graphical Abstract BackgroundThe key role of thrombospondin 1 (THBS1) in the pathogenesis of acute-on-chronic liver failure (ACLF) is unclear. Here, we present a transcriptome approach to evaluate THBS1 as a potential biomarker in ACLF disease pathogenesis.MethodsBiobanked peripheral blood mononuclear cells (PBMCs) from 330 subjects with hepatitis B virus (HBV)-related etiologies, including HBV-ACLF, liver cirrhosis (LC), and chronic hepatitis B (CHB), and normal controls (NC) randomly selected from the Chinese Group on the Study of Severe Hepatitis B (COSSH) prospective multicenter cohort underwent transcriptome analyses (ACLF = 20; LC = 10; CHB = 10; NC = 15); the findings were externally validated in participants from COSSH cohort, an ACLF rat model and hepatocyte-specific THBS1 knockout mice.ResultsTHBS1 was the top significantly differentially expressed gene in the PBMC transcriptome, with the most significant upregulation in ACLF, and quantitative polymerase chain reaction (ACLF = 110; LC = 60; CHB = 60; NC = 45) was used to verify that THBS1 expression corresponded to ACLF disease severity outcome, including inflammation and hepatocellular apoptosis. THBS1 showed good predictive ability for ACLF short-term mortality, with an area under the receiver operating characteristic curve (AUROC) of 0.8438 and 0.7778 at 28 and 90 days, respectively. Enzyme-linked immunosorbent assay validation of the plasma THBS1 using an expanded COSSH cohort subjects (ACLF = 198; LC = 50; CHB = 50; NC = 50) showed significant correlation between THBS1 with ALT and γ-GT (P = 0.01), and offered a similarly good prognostication predictive ability (AUROC = 0.7445 and 0.7175) at 28 and 90 days, respectively. ACLF patients with high-risk short-term mortality were identified based on plasma THBS1 optimal cut-off value (< 28 µg/ml). External validation in ACLF rat serum and livers confirmed the functional association between THBS1, the immune response and hepatocellular apoptosis. Hepatocyte-specific THBS1 knockout improved mouse survival, significantly repressed major inflammatory cytokines, enhanced the expression of several anti-inflammatory mediators and impeded hepatocellular apoptosis.ConclusionsTHBS1 might be an ACLF disease development-related biomarker, promoting inflammatory responses and hepatocellular apoptosis, that could provide clinicians with a new molecular target for improving diagnostic and therapeutic strategies. Background The key role of thrombospondin 1 (THBS1) in the pathogenesis of acute-on-chronic liver failure (ACLF) is unclear. Here, we present a transcriptome approach to evaluate THBS1 as a potential biomarker in ACLF disease pathogenesis. Methods Biobanked peripheral blood mononuclear cells (PBMCs) from 330 subjects with hepatitis B virus (HBV)-related etiologies, including HBV-ACLF, liver cirrhosis (LC), and chronic hepatitis B (CHB), and normal controls (NC) randomly selected from the Chinese Group on the Study of Severe Hepatitis B (COSSH) prospective multicenter cohort underwent transcriptome analyses (ACLF = 20; LC = 10; CHB = 10; NC = 15); the findings were externally validated in participants from COSSH cohort, an ACLF rat model and hepatocyte-specific THBS1 knockout mice. Results THBS1 was the top significantly differentially expressed gene in the PBMC transcriptome, with the most significant upregulation in ACLF, and quantitative polymerase chain reaction (ACLF = 110; LC = 60; CHB = 60; NC = 45) was used to verify that THBS1 expression corresponded to ACLF disease severity outcome, including inflammation and hepatocellular apoptosis. THBS1 showed good predictive ability for ACLF short-term mortality, with an area under the receiver operating characteristic curve (AUROC) of 0.8438 and 0.7778 at 28 and 90 days, respectively. Enzyme-linked immunosorbent assay validation of the plasma THBS1 using an expanded COSSH cohort subjects (ACLF = 198; LC = 50; CHB = 50; NC = 50) showed significant correlation between THBS1 with ALT and γ-GT ( P = 0.01), and offered a similarly good prognostication predictive ability (AUROC = 0.7445 and 0.7175) at 28 and 90 days, respectively. ACLF patients with high-risk short-term mortality were identified based on plasma THBS1 optimal cut-off value (< 28 µg/ml). External validation in ACLF rat serum and livers confirmed the functional association between THBS1, the immune response and hepatocellular apoptosis. Hepatocyte-specific THBS1 knockout improved mouse survival, significantly repressed major inflammatory cytokines, enhanced the expression of several anti-inflammatory mediators and impeded hepatocellular apoptosis. Conclusions THBS1 might be an ACLF disease development-related biomarker, promoting inflammatory responses and hepatocellular apoptosis, that could provide clinicians with a new molecular target for improving diagnostic and therapeutic strategies. Graphical Abstract |
| ArticleNumber | 95 |
| Audience | Academic |
| Author | Jiang, Jing Shi, Dongyan Luo, Jinjin Ren, Keke Chen, Qi Yang, Hui Li, Jun Guo, Beibei Lu, Yingyan Li, Jiang Hassan, Hozeifa Mohamed Cai, Qun Xin, Jiaojiao Li, Peng Yao, Heng Zhou, Xingping Hu, Wen Liang, Xi |
| Author_xml | – sequence: 1 givenname: Hozeifa Mohamed orcidid: 0000-0001-9463-6007 surname: Hassan fullname: Hassan, Hozeifa Mohamed organization: Precision Medicine Center, Taizhou Central Hospital (Taizhou University Hospital), State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine – sequence: 2 givenname: Xi surname: Liang fullname: Liang, Xi organization: Precision Medicine Center, Taizhou Central Hospital (Taizhou University Hospital) – sequence: 3 givenname: Jiaojiao surname: Xin fullname: Xin, Jiaojiao organization: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine – sequence: 4 givenname: Yingyan surname: Lu fullname: Lu, Yingyan organization: Key Laboratory of Cancer Prevention and Therapy Combining Traditional Chinese and Western Medicine, Tongde Hospital of Zhejiang Province – sequence: 5 givenname: Qun surname: Cai fullname: Cai, Qun organization: Department of Infectious Diseases and Liver Diseases, Ningbo Medical Center Lihuili Hospital, Affiliated Lihuili Hospital of Ningbo University – sequence: 6 givenname: Dongyan surname: Shi fullname: Shi, Dongyan organization: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine – sequence: 7 givenname: Keke surname: Ren fullname: Ren, Keke organization: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine – sequence: 8 givenname: Jun surname: Li fullname: Li, Jun organization: Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine – sequence: 9 givenname: Qi surname: Chen fullname: Chen, Qi organization: Precision Medicine Center, Taizhou Central Hospital (Taizhou University Hospital) – sequence: 10 givenname: Jiang surname: Li fullname: Li, Jiang organization: Department of Infectious Disease, The First Affiliated Hospital of Anhui Medical University – sequence: 11 givenname: Peng surname: Li fullname: Li, Peng organization: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine – sequence: 12 givenname: Beibei surname: Guo fullname: Guo, Beibei organization: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine – sequence: 13 givenname: Hui surname: Yang fullname: Yang, Hui organization: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine – sequence: 14 givenname: Jinjin surname: Luo fullname: Luo, Jinjin organization: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine – sequence: 15 givenname: Heng surname: Yao fullname: Yao, Heng organization: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine – sequence: 16 givenname: Xingping surname: Zhou fullname: Zhou, Xingping organization: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine – sequence: 17 givenname: Wen surname: Hu fullname: Hu, Wen organization: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine – sequence: 18 givenname: Jing surname: Jiang fullname: Jiang, Jing email: jiangjingzju@zju.edu.cn organization: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine – sequence: 19 givenname: Jun orcidid: 0000-0002-7236-8088 surname: Li fullname: Li, Jun email: lijun2009@zju.edu.cn organization: Precision Medicine Center, Taizhou Central Hospital (Taizhou University Hospital), State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38439091$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9Ustq3DAUNSWlebQ_0EUxFEo2TvWyZa1KCH0EAt2kayHLVzMaZGkq2SHz95Vn8pgJJWghcXXOudK557Q48sFDUXzE6ALjtvmaMBG4qRBhFaIUt9X9m-IEc4YrjnB9tHc-Lk5TWiFEas7Zu-KYtowKJPBJYW6XMQxdSOvge-tLXIJfKq8hlWmTRhisLq03Tg2DGm3wpfJ92dsEKkGZ4A6iHTcZUSo9jVAFX-ks6DPL2XxZGmXdFOF98dYol-DDw35W_Pnx_fbqV3Xz--f11eVNpRsqxkp3xDBhTCPqnlDd0h4YaojRmBmsDEVAOiIEMq1hvFWdBsxrJhgwzDTmiJ4V1zvdPqiVXEc7qLiRQVm5LYS4kCqOVjuQyBgqGqU50YpprTvTC97xRhnctZ1mWevbTms9dQP0GvwYlTsQPbzxdikX4U7i7Cxl7fya8weFGP5OkEY52KTBOeUhTEkSQTlHNWFzs88voKswRZ-9yqi6aRvKRP2MWqj8gzyXkBvrWVRe8ramiGE0a138B5VXP48zZ8jYXD8gfNkjLEG5cZmCm-aBp0Pgp31Lnrx4zFMGkB1Ax5BSBPMEwUjOoZW70MocWrkNrbzPpPYFSdtxm7b8butep9IdNeU-fgHx2bZXWP8A2P0BUA |
| CitedBy_id | crossref_primary_10_1186_s43042_024_00572_9 crossref_primary_10_1186_s12916_025_03931_4 |
| Cites_doi | 10.1016/j.jhep.2021.06.035 10.1136/gutjnl-2017-314641 10.1002/hep.27795 10.1111/liv.13503 10.1136/gut.2004.042911 10.1053/j.gastro.2013.02.042 10.1002/hep.24800 10.1016/j.cell.2012.03.050 10.1016/j.intimp.2017.08.009 10.1016/j.metabol.2014.03.008 10.1038/cmi.2013.32 10.1371/journal.pone.0226854 10.1371/journal.pone.0048535 10.2174/138945008785909347 10.1161/CIRCRESAHA.117.305262 10.1038/nmeth.3317 10.1111/hepr.12787 10.3390/cancers12020255 10.1136/gutjnl-2020-323395 10.1055/s-0036-1583200 10.1172/JCI130197 10.3389/fendo.2021.638536 10.1155/2011/296069 10.1016/j.jhep.2022.10.031 10.1016/S0140-6736(15)00309-8 10.1038/71517 10.1158/1078-0432.CCR-04-0713 10.26508/lsa.202101189 10.1016/j.jhep.2020.11.048 10.1016/j.ajpath.2013.06.029 10.1002/bjs.9814 10.1016/j.jhep.2021.05.026 10.1038/s41467-018-06318-7 10.1016/j.clinre.2015.06.009 10.1016/j.jhep.2015.01.029 10.3390/cells9051175 10.1007/s12072-022-10472-y 10.1258/002367786780808686 10.1016/j.cgh.2022.03.016 10.1016/j.taap.2020.115323 10.1016/j.jhep.2015.11.021 10.4049/jimmunol.177.6.3534 10.1016/j.jhep.2018.01.008 10.1084/jem.20030705 10.1136/gutjnl-2020-323973 10.1016/j.jhep.2019.11.009 10.1016/j.ajpath.2019.10.003 10.1038/nprot.2016.095 10.1016/j.jss.2016.10.007 10.1016/j.ophtha.2014.01.033 10.1038/srep20759 10.1186/s13054-023-04540-4 10.1101/cshperspect.a006627 10.1002/hep.28156 10.14218/JCTH.2022.00086 10.1371/journal.pone.0026838 10.1016/j.jhep.2012.06.026 10.1002/jmv.28183 10.14309/ajg.0000000000000201 10.1038/nbt.3122 10.1056/NEJMra1914900 10.1002/hep.27077 10.1006/meth.2001.1262 10.1016/j.metabol.2015.07.016 10.1016/j.eng.2020.12.013 10.1038/ki.2012.21 10.1155/2021/5545181 10.1016/j.jhep.2020.11.035 10.2147/IDR.S417472 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2024 2024. The Author(s). COPYRIGHT 2024 BioMed Central Ltd. 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2024 – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 BioMed Central Ltd. – notice: 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7U9 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR C1K CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P M7N PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM DOA |
| DOI | 10.1186/s12916-024-03318-x |
| DatabaseName | Springer Nature Link CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central Environmental Sciences and Pollution Management ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) ProQuest One Academic ProQuest One Academic (New) ProQuest - Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Environmental Sciences and Pollution Management ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals (Selected full-text) url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1741-7015 |
| EndPage | 17 |
| ExternalDocumentID | oai_doaj_org_article_0ff396ac72ca4cccbfd97b76af1b8bc4 PMC10913480 A785304104 38439091 10_1186_s12916_024_03318_x |
| Genre | Research Support, Non-U.S. Gov't Multicenter Study Journal Article |
| GeographicLocations | China United States--US |
| GeographicLocations_xml | – name: China – name: United States--US |
| GrantInformation_xml | – fundername: National Key R&D Program of China grantid: 2022YFC2304800; 2022YFA1104600 – fundername: National Natural Science Foundation of China grantid: 81830073; 32330057; 82272426; 82370634 funderid: http://dx.doi.org/10.13039/501100001809 – fundername: National and Zhejiang Provincial Special Support Program for High-Level Personnel Recruitment (Ten-thousand Talents Program) – fundername: National Key R&D Program of China grantid: 2022YFA1104100 – fundername: National Natural Science Foundation of China grantid: 32330057 – fundername: National Natural Science Foundation of China grantid: 82272426 – fundername: National Key R&D Program of China grantid: 2022YFC2304800 – fundername: National Key R&D Program of China grantid: 2022YFA1104600 – fundername: National Natural Science Foundation of China grantid: 81830073 – fundername: National Natural Science Foundation of China grantid: 82370634 |
| GroupedDBID | --- 0R~ 23N 2WC 4.4 53G 5GY 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR IHW INH INR ITC KQ8 M1P M48 MK0 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP WOQ WOW XSB AAYXX ALIPV CITATION -5E -5G -A0 -BR 3V. ACRMQ ADINQ C24 CGR CUY CVF ECM EIF NPM PMFND 7QL 7U9 7XB 8FK AZQEC C1K DWQXO H94 K9. M7N PKEHL PQEST PQUKI 7X8 5PM |
| ID | FETCH-LOGICAL-c639t-cb2f49ff695d23c83de4062fc14f1af30e2b2990f8f478abce175494e414c1703 |
| IEDL.DBID | 7X7 |
| ISSN | 1741-7015 |
| IngestDate | Wed Aug 27 01:25:21 EDT 2025 Thu Aug 21 18:35:37 EDT 2025 Thu Sep 04 16:55:51 EDT 2025 Sat Jul 26 00:18:27 EDT 2025 Tue Jun 17 22:18:23 EDT 2025 Tue Jun 10 21:11:08 EDT 2025 Thu May 22 21:24:21 EDT 2025 Wed Feb 19 02:04:38 EST 2025 Thu Apr 24 23:07:03 EDT 2025 Tue Jul 01 02:51:38 EDT 2025 Sat Sep 06 07:25:01 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Acute-on-chronic liver failure Inflammatory response Immune-metabolism disorder Thrombospondin 1 Hepatocellular apoptosis Severity prediction |
| Language | English |
| License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c639t-cb2f49ff695d23c83de4062fc14f1af30e2b2990f8f478abce175494e414c1703 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0001-9463-6007 0000-0002-7236-8088 |
| OpenAccessLink | https://www.proquest.com/docview/2956863495?pq-origsite=%requestingapplication% |
| PMID | 38439091 |
| PQID | 2956863495 |
| PQPubID | 42775 |
| PageCount | 17 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_0ff396ac72ca4cccbfd97b76af1b8bc4 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10913480 proquest_miscellaneous_2937705244 proquest_journals_2956863495 gale_infotracmisc_A785304104 gale_infotracacademiconefile_A785304104 gale_healthsolutions_A785304104 pubmed_primary_38439091 crossref_primary_10_1186_s12916_024_03318_x crossref_citationtrail_10_1186_s12916_024_03318_x springer_journals_10_1186_s12916_024_03318_x |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-03-05 |
| PublicationDateYYYYMMDD | 2024-03-05 |
| PublicationDate_xml | – month: 03 year: 2024 text: 2024-03-05 day: 05 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | BMC medicine |
| PublicationTitleAbbrev | BMC Med |
| PublicationTitleAlternate | BMC Med |
| PublicationYear | 2024 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | Z Lopez-Dee (3318_CR57) 2011; 2011 N Gehrke (3318_CR24) 2018; 68 J Cai (3318_CR44) 2016; 40 B Jimenez (3318_CR66) 2000; 6 FM Trovato (3318_CR70) 2023; 78 J Yao (3318_CR47) 2023; 17 SA MacParland (3318_CR41) 2018; 9 ZB Wu (3318_CR42) 2021; 2021 P Desai (3318_CR64) 2017; 210 J Luo (3318_CR39) 2023; 21 G Frampton (3318_CR52) 2020; 409 J Min-DeBartolo (3318_CR63) 2019; 14 P Starlinger (3318_CR53) 2015; 102 T Wu (3318_CR15) 2018; 67 J Li (3318_CR7) 2022; 71 H Li (3318_CR69) 2015; 63 Y Li (3318_CR13) 2017; 47 Y Shi (3318_CR34) 2015; 62 Z Zheng (3318_CR23) 2022; 14 N Bige (3318_CR62) 2012; 81 JP McMorrow (3318_CR49) 2013; 183 J Luo (3318_CR3) 2023; 27 S Sun (3318_CR28) 2011; 6 V Arroyo (3318_CR2) 2020; 382 W Bernal (3318_CR31) 2015; 386 V Doyen (3318_CR60) 2003; 198 J Luo (3318_CR40) 2023; 95 AM Bolger (3318_CR18) 2014; 30 K Breitkopf (3318_CR58) 2005; 54 ER Parra (3318_CR27) 2020; 12 Z Liu (3318_CR10) 2015; 117 KJ Livak (3318_CR25) 2001; 25 X Liu (3318_CR54) 2014; 63 PR Lawler (3318_CR67) 2012; 2 MC Nielsen (3318_CR36) 2020; 9 V Arroyo (3318_CR5) 2021; 74 RP Mookerjee (3318_CR38) 2016; 36 L Contreras-Ruiz (3318_CR50) 2014; 121 M Schulz (3318_CR1) 2022; 71 JM Lynch (3318_CR59) 2012; 149 B Jefferson (3318_CR11) 2020; 190 D Kim (3318_CR19) 2015; 12 Q Zhou (3318_CR14) 2016; 6 M Pertea (3318_CR21) 2016; 11 G Zaccherini (3318_CR6) 2021; 74 K Imaoka (3318_CR71) 1986; 20 S Monteiro (3318_CR46) 2021; 70 L Li (3318_CR29) 2017; 51 D Wu (3318_CR35) 2020; 130 A Granito (3318_CR8) 2021; 75 NA Terrault (3318_CR16) 2016; 63 XX Du (3318_CR45) 2018; 38 J Li (3318_CR17) 2021; 75 D Ortiz-Masia (3318_CR51) 2012; 7 R Moreau (3318_CR32) 2013; 144 G Qin (3318_CR43) 2023; 16 LS Gutierrez (3318_CR56) 2021; 12 H Devarbhavi (3318_CR9) 2019; 114 R Jalan (3318_CR30) 2012; 57 P Grimbert (3318_CR12) 2006; 177 RL Camp (3318_CR26) 2004; 10 Y Li (3318_CR61) 2013; 10 HM Hassan (3318_CR55) 2022; 10 JS Bajaj (3318_CR33) 2014; 60 H Hayashi (3318_CR65) 2012; 55 M Pertea (3318_CR20) 2015; 33 HM Hassan (3318_CR22) 2022; 5 Y Mirochnik (3318_CR68) 2008; 9 Y Matsuo (3318_CR48) 2015; 64 H Grønbæk (3318_CR37) 2016; 64 R Moreau (3318_CR4) 2020; 72 |
| References_xml | – volume: 75 start-page: 1503 issue: 6 year: 2021 ident: 3318_CR8 publication-title: J Hepatol doi: 10.1016/j.jhep.2021.06.035 – volume: 67 start-page: 2181 issue: 12 year: 2018 ident: 3318_CR15 publication-title: Gut doi: 10.1136/gutjnl-2017-314641 – volume: 62 start-page: 232 issue: 1 year: 2015 ident: 3318_CR34 publication-title: Hepatology doi: 10.1002/hep.27795 – volume: 38 start-page: 229 issue: 2 year: 2018 ident: 3318_CR45 publication-title: Liver Int doi: 10.1111/liv.13503 – volume: 54 start-page: 673 issue: 5 year: 2005 ident: 3318_CR58 publication-title: Gut doi: 10.1136/gut.2004.042911 – volume: 144 start-page: 1426 issue: 7 year: 2013 ident: 3318_CR32 publication-title: Gastroenterology doi: 10.1053/j.gastro.2013.02.042 – volume: 55 start-page: 1562 issue: 5 year: 2012 ident: 3318_CR65 publication-title: Hepatology doi: 10.1002/hep.24800 – volume: 149 start-page: 1257 issue: 6 year: 2012 ident: 3318_CR59 publication-title: Cell doi: 10.1016/j.cell.2012.03.050 – volume: 51 start-page: 99 year: 2017 ident: 3318_CR29 publication-title: Int Immunopharmacol doi: 10.1016/j.intimp.2017.08.009 – volume: 63 start-page: 773 issue: 6 year: 2014 ident: 3318_CR54 publication-title: Metab Clin Exp doi: 10.1016/j.metabol.2014.03.008 – volume: 10 start-page: 506 issue: 6 year: 2013 ident: 3318_CR61 publication-title: Cell Mol Immunol doi: 10.1038/cmi.2013.32 – volume: 14 start-page: e0226854 issue: 12 year: 2019 ident: 3318_CR63 publication-title: PLoS One doi: 10.1371/journal.pone.0226854 – volume: 7 start-page: e48535 issue: 10 year: 2012 ident: 3318_CR51 publication-title: PLoS One doi: 10.1371/journal.pone.0048535 – volume: 9 start-page: 851 issue: 10 year: 2008 ident: 3318_CR68 publication-title: Curr Drug Targets doi: 10.2174/138945008785909347 – volume: 117 start-page: 129 issue: 2 year: 2015 ident: 3318_CR10 publication-title: Circ Res doi: 10.1161/CIRCRESAHA.117.305262 – volume: 12 start-page: 357 issue: 4 year: 2015 ident: 3318_CR19 publication-title: Nat Methods doi: 10.1038/nmeth.3317 – volume: 47 start-page: 186 issue: 2 year: 2017 ident: 3318_CR13 publication-title: Hepatol Res doi: 10.1111/hepr.12787 – volume: 12 start-page: 255 issue: 2 year: 2020 ident: 3318_CR27 publication-title: Cancers (Basel) doi: 10.3390/cancers12020255 – volume: 71 start-page: 163 issue: 1 year: 2022 ident: 3318_CR7 publication-title: Gut doi: 10.1136/gutjnl-2020-323395 – volume: 36 start-page: 127 issue: 2 year: 2016 ident: 3318_CR38 publication-title: Semin Liver Dis doi: 10.1055/s-0036-1583200 – volume: 130 start-page: 2069 issue: 4 year: 2020 ident: 3318_CR35 publication-title: J Clin Investig doi: 10.1172/JCI130197 – volume: 12 start-page: 638536 year: 2021 ident: 3318_CR56 publication-title: Front Endocrinol doi: 10.3389/fendo.2021.638536 – volume: 2011 start-page: 296069 year: 2011 ident: 3318_CR57 publication-title: Mediators Inflamm doi: 10.1155/2011/296069 – volume: 78 start-page: 558 issue: 3 year: 2023 ident: 3318_CR70 publication-title: J Hepatol doi: 10.1016/j.jhep.2022.10.031 – volume: 386 start-page: 1576 issue: 10003 year: 2015 ident: 3318_CR31 publication-title: Lancet doi: 10.1016/S0140-6736(15)00309-8 – volume: 6 start-page: 41 issue: 1 year: 2000 ident: 3318_CR66 publication-title: Nat Med doi: 10.1038/71517 – volume: 10 start-page: 7252 issue: 21 year: 2004 ident: 3318_CR26 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-04-0713 – volume: 70 start-page: 379 issue: 2 year: 2021 ident: 3318_CR46 publication-title: Gut – volume: 5 start-page: e202101189 issue: 3 year: 2022 ident: 3318_CR22 publication-title: Life Sci Alliance doi: 10.26508/lsa.202101189 – volume: 74 start-page: 670 issue: 3 year: 2021 ident: 3318_CR5 publication-title: J Hepatol doi: 10.1016/j.jhep.2020.11.048 – volume: 183 start-page: 1243 issue: 4 year: 2013 ident: 3318_CR49 publication-title: Am J Pathol doi: 10.1016/j.ajpath.2013.06.029 – volume: 102 start-page: 826 issue: 7 year: 2015 ident: 3318_CR53 publication-title: Br J Surg doi: 10.1002/bjs.9814 – volume: 75 start-page: 1104 issue: 5 year: 2021 ident: 3318_CR17 publication-title: J Hepatol doi: 10.1016/j.jhep.2021.05.026 – volume: 30 start-page: 2114 issue: 15 year: 2014 ident: 3318_CR18 publication-title: Bioinformatics (Oxford, England) – volume: 9 start-page: 4383 issue: 1 year: 2018 ident: 3318_CR41 publication-title: Nat Commun doi: 10.1038/s41467-018-06318-7 – volume: 40 start-page: 41 issue: 1 year: 2016 ident: 3318_CR44 publication-title: Clin Res Hepatol Gastroenterol doi: 10.1016/j.clinre.2015.06.009 – volume: 63 start-page: 50 issue: 1 year: 2015 ident: 3318_CR69 publication-title: J Hepatol doi: 10.1016/j.jhep.2015.01.029 – volume: 9 start-page: 1175 issue: 5 year: 2020 ident: 3318_CR36 publication-title: Cells doi: 10.3390/cells9051175 – volume: 17 start-page: 676 issue: 3 year: 2023 ident: 3318_CR47 publication-title: Hepatol Int doi: 10.1007/s12072-022-10472-y – volume: 20 start-page: 321 issue: 4 year: 1986 ident: 3318_CR71 publication-title: Lab Anim doi: 10.1258/002367786780808686 – volume: 21 start-page: 681 issue: 3 year: 2023 ident: 3318_CR39 publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2022.03.016 – volume: 409 start-page: 115323 year: 2020 ident: 3318_CR52 publication-title: Toxicol Appl Pharmacol doi: 10.1016/j.taap.2020.115323 – volume: 64 start-page: 813 issue: 4 year: 2016 ident: 3318_CR37 publication-title: J Hepatol doi: 10.1016/j.jhep.2015.11.021 – volume: 177 start-page: 3534 issue: 6 year: 2006 ident: 3318_CR12 publication-title: J Immunol doi: 10.4049/jimmunol.177.6.3534 – volume: 68 start-page: 986 issue: 5 year: 2018 ident: 3318_CR24 publication-title: J Hepatol doi: 10.1016/j.jhep.2018.01.008 – volume: 198 start-page: 1277 issue: 8 year: 2003 ident: 3318_CR60 publication-title: J Exp Med doi: 10.1084/jem.20030705 – volume: 71 start-page: 5 issue: 1 year: 2022 ident: 3318_CR1 publication-title: Gut doi: 10.1136/gutjnl-2020-323973 – volume: 72 start-page: 688 issue: 4 year: 2020 ident: 3318_CR4 publication-title: J Hepatol doi: 10.1016/j.jhep.2019.11.009 – volume: 190 start-page: 347 issue: 2 year: 2020 ident: 3318_CR11 publication-title: Am J Pathol doi: 10.1016/j.ajpath.2019.10.003 – volume: 11 start-page: 1650 issue: 9 year: 2016 ident: 3318_CR21 publication-title: Nat Protoc doi: 10.1038/nprot.2016.095 – volume: 210 start-page: 1 year: 2017 ident: 3318_CR64 publication-title: J Surg Res doi: 10.1016/j.jss.2016.10.007 – volume: 121 start-page: 1389 issue: 7 year: 2014 ident: 3318_CR50 publication-title: Ophthalmology doi: 10.1016/j.ophtha.2014.01.033 – volume: 6 start-page: 20759 year: 2016 ident: 3318_CR14 publication-title: Sci Rep doi: 10.1038/srep20759 – volume: 27 start-page: 259 issue: 1 year: 2023 ident: 3318_CR3 publication-title: Crit Care doi: 10.1186/s13054-023-04540-4 – volume: 2 start-page: a006627 issue: 5 year: 2012 ident: 3318_CR67 publication-title: Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a006627 – volume: 63 start-page: 261 issue: 1 year: 2016 ident: 3318_CR16 publication-title: Hepatology doi: 10.1002/hep.28156 – volume: 10 start-page: 995 issue: 5 year: 2022 ident: 3318_CR55 publication-title: J Clin Transl Hepatol doi: 10.14218/JCTH.2022.00086 – volume: 6 start-page: e26838 issue: 11 year: 2011 ident: 3318_CR28 publication-title: PLoS One doi: 10.1371/journal.pone.0026838 – volume: 57 start-page: 1336 issue: 6 year: 2012 ident: 3318_CR30 publication-title: J Hepatol doi: 10.1016/j.jhep.2012.06.026 – volume: 95 start-page: e28183 issue: 1 year: 2023 ident: 3318_CR40 publication-title: J Med Virol doi: 10.1002/jmv.28183 – volume: 114 start-page: 929 issue: 6 year: 2019 ident: 3318_CR9 publication-title: Am J Gastroenterol doi: 10.14309/ajg.0000000000000201 – volume: 33 start-page: 290 issue: 3 year: 2015 ident: 3318_CR20 publication-title: Nat Biotechnol doi: 10.1038/nbt.3122 – volume: 382 start-page: 2137 issue: 22 year: 2020 ident: 3318_CR2 publication-title: N Engl J Med doi: 10.1056/NEJMra1914900 – volume: 60 start-page: 250 issue: 1 year: 2014 ident: 3318_CR33 publication-title: Hepatology (Baltimore, MD) doi: 10.1002/hep.27077 – volume: 25 start-page: 402 issue: 4 year: 2001 ident: 3318_CR25 publication-title: Methods (San Diego, Calif) doi: 10.1006/meth.2001.1262 – volume: 64 start-page: 1490 issue: 11 year: 2015 ident: 3318_CR48 publication-title: Metab Clin Exp doi: 10.1016/j.metabol.2015.07.016 – volume: 14 start-page: 134 year: 2022 ident: 3318_CR23 publication-title: Engineering doi: 10.1016/j.eng.2020.12.013 – volume: 81 start-page: 1226 issue: 12 year: 2012 ident: 3318_CR62 publication-title: Kidney Int doi: 10.1038/ki.2012.21 – volume: 2021 start-page: 5545181 year: 2021 ident: 3318_CR42 publication-title: Can J Gastroenterol Hepatol doi: 10.1155/2021/5545181 – volume: 74 start-page: 1117 issue: 5 year: 2021 ident: 3318_CR6 publication-title: J Hepatol doi: 10.1016/j.jhep.2020.11.035 – volume: 16 start-page: 5765 year: 2023 ident: 3318_CR43 publication-title: Infect Drug Resist doi: 10.2147/IDR.S417472 |
| SSID | ssj0025774 |
| Score | 2.466568 |
| Snippet | Background
The key role of thrombospondin 1 (THBS1) in the pathogenesis of acute-on-chronic liver failure (ACLF) is unclear. Here, we present a transcriptome... The key role of thrombospondin 1 (THBS1) in the pathogenesis of acute-on-chronic liver failure (ACLF) is unclear. Here, we present a transcriptome approach to... Background The key role of thrombospondin 1 (THBS1) in the pathogenesis of acute-on-chronic liver failure (ACLF) is unclear. Here, we present a transcriptome... BackgroundThe key role of thrombospondin 1 (THBS1) in the pathogenesis of acute-on-chronic liver failure (ACLF) is unclear. Here, we present a transcriptome... Abstract Background The key role of thrombospondin 1 (THBS1) in the pathogenesis of acute-on-chronic liver failure (ACLF) is unclear. Here, we present a... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 95 |
| SubjectTerms | Acute-On-Chronic Liver Failure Analysis Animals Apoptosis Biological markers Biomarkers Biomedicine Care and treatment Cirrhosis Development and progression Enzyme-linked immunosorbent assay Enzymes Genes Health aspects Hepatitis Hepatitis B Hepatitis B virus Hepatocellular apoptosis Humans Immune response Immune system Immune-metabolism disorder Inflammation Inflammatory response Leukocytes, Mononuclear Liver Liver cancer Liver Cirrhosis Liver diseases Liver failure Liver transplants Medical prognosis Medicine Medicine & Public Health Metabolism Mice Molecular mechanics Mortality Pathogenesis Pathogens Peripheral blood mononuclear cells Phenotype Polymerase chain reaction Prospective Studies Rats Research Article Risk factors Severity prediction Survival analysis Thrombospondin Thrombospondin 1 Thrombospondin 1 - genetics Transcriptomes |
| SummonAdditionalLinks | – databaseName: DOAJ dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gLojwDBYyExAGsJo7jOMeCqCqkcmql3ixnYmtXKgnq7kr9-czYSdoUAReu8SRK5u145hvG3rsQyjzQfJfSeaE6p4STQQr0lk2Xy0YpoP8dp9_1ybn6dlFd3Br1RTVhCR44Me4wx4c12kEtwSkAaEPX1G2tXSha00JEAsUwNm2mxq1WhVnN1CJj9OEGo1pBxbZK5CVqsbhehKGI1v-7T74VlO4WTN45NY3B6PgRezhmkfwovf0-u-f7x-z-6XhO_oSFs9XV8KMdqP4VgxMvuO9XJN8NT9DNa-CoWqgNqXORu77j41kNx1jpaaQdUnAHu60XQy8ggejyS6rj4MGtqZz9KTs__nr25USMExUEYCayFdDKoJoQdFN1sgRTdh4DugxQqFA4lJqXLcWnYIKqjWvBY3ahGuVVoaBA5_CM7fVD718wjnlbHqDUXSUJYs4ZHchdFN6XQRujMlZMDLYwwo3T1ItLG7cdRtskFItCsVEo9jpjH-d7fiawjb9Sfya5zZQElB0voPrYUX3sv9QnY29J6jZ1nc7mbo9qzGNyhZvVjH2IFGTw-AHgxr4FZANBZy0oDxaUaKiwXJ40y46OYmMltWvqErepGXs3L9OdVPzW-2FHNGVd5xUmYhl7nhRx_ujSYEaJOV_GzEJFF1xZrvTrVYQRj5CwyuQZ-zRp8817_ZntL_8H21-xBzJZo8irA7a3vdr515jdbds30ZB_AX3eTT4 priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZKkRAXxJtAASMhOIAhsb2Oc0CoIKoKaTl1pd4sx7G7Ky1Juw9p-ffMOA9IKb2uJ6t45hvPOPMi5LUNQaQB57sI65msrGSWB87gtCyqlBdSOvzeMf2hjmfy--nkdI_06bYdA9dXXu1wntRstfywu_j1GRT-U1R4rT6uwWZlmEorWSoAo2z35vyC4WApDMB2UzZukJtgrDgCfyqHQAMANpd9Lc2VfzWyV7Gt_7-H91_W63Jm5aXwarRaR3fJnc7dpIctPu6RPV_fJ7emXUD9AQkn81Xzs2wwURasGM2or-cIhDVtezwvHAWuAGzaEkdq64p2QR0KRtXj7DugoNZtN541NXNtt126xIQPGuwC894fktnRt5Ovx6wbvcAcuCwb5koeZBGCKiYVF06LyoPl58FlMmQWxOt5iYYs6CBzbUvnwQ2RhfQyky6DU-QR2a-b2j8hFBy8NDihqgnHXnRWq4DnSua9CEprmZCsZ7BxXV9yHI-xNPF-opVphWJAKCYKxewS8m545rztynEt9ReU20CJHbXjD83qzHQKalIAbaGsy7mz0jlXhqrIy1zZkJW6dPCaL1Hqpi1PHc4Fc5iDw5NKuNUm5G2kQKzCBpztChyADdhja0R5MKIEjXbj5R5ZplcIw7GuUwm4zybk1bCMT2KWXO2bLdKIPE8n4LEl5HELxGHTQoPrCc5hQvQIoiOujFfqxTz2G4-9Y6VOE_K-R_Of9_o_259ev41n5DZv9YylkwOyv1lt_XNw8Dbli6iivwHCG01u priority: 102 providerName: Scholars Portal – databaseName: Springer Nature Link dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3da9UwFA8yQXwR3fyozhlB8EGDzUfT9HFeHGMwnzbYW0hPE-6F2cruveCf7zltb13nB_janECb8_VLc84vjL0LKek80f0uOkRhmmBEUEkJjJZVk6vKGKD_Hedf7emlObsqrkaaHOqFuX1-L539tMZ8JKlM1ohco_0JxIv3Cwy8VL63sItpc1Ugjtk1xfxx3izx9Pz8v0fhW2nobonknXPSPv2cPGaPRtzIjwdFP2H3YrvPHpyPJ-MHLF0sb7pvdUcVr5iOuOSxXZJG13wga14BR2NC_Q-9ijy0DR9PZzhmx0iX2KEED7DdRNG1AgbaXH5NlRs8hRUVsD9llydfLhanYrxDQQBij42AWiVTpWSrolEanG4ipnCVQJokA-opqpoyUnLJlC7UEBFPmMpEIw1IDAfP2F7btfEF44jU8gTaNoUiUrngbKIAIWPUyTpnMiZ3C-xhJBiney6ufb_RcNYPSvGoFN8rxf_I2IdpzveBXuOf0p9Jb5MkUWP3D9Bi_OhpPkfrq2yAUkEwAFCnpirr0oYka1cDvuYb0rof-kwnB_fHJSKX3OD2NGPvewlycfwACGOnAi4DkWXNJA9nkuiaMB_eWZYfQ8PaK2rQtBo3phl7Ow3TTCp3a2O3JRldlnmB0CtjzwdDnD5aO8SQiPIy5mYmOluV-Ui7WvbE4T0JrHF5xj7urPnXe_192V_-n_gr9lANfify4pDtbW628TUit0191LvsT5CNO8E priority: 102 providerName: Springer Nature |
| Title | Thrombospondin 1 enhances systemic inflammation and disease severity in acute-on-chronic liver failure |
| URI | https://link.springer.com/article/10.1186/s12916-024-03318-x https://www.ncbi.nlm.nih.gov/pubmed/38439091 https://www.proquest.com/docview/2956863495 https://www.proquest.com/docview/2937705244 https://pubmed.ncbi.nlm.nih.gov/PMC10913480 https://doaj.org/article/0ff396ac72ca4cccbfd97b76af1b8bc4 |
| Volume | 22 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMed Central Open Access Free customDbUrl: eissn: 1741-7015 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0025774 issn: 1741-7015 databaseCode: RBZ dateStart: 20030101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAFT databaseName: Colorado Digital library customDbUrl: eissn: 1741-7015 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0025774 issn: 1741-7015 databaseCode: KQ8 dateStart: 20031101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAFT databaseName: Colorado Digital library customDbUrl: eissn: 1741-7015 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0025774 issn: 1741-7015 databaseCode: KQ8 dateStart: 20030101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1741-7015 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0025774 issn: 1741-7015 databaseCode: DOA dateStart: 20030101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVEBS databaseName: EBSCOhost Academic Search Ultimate customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 1741-7015 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0025774 issn: 1741-7015 databaseCode: ABDBF dateStart: 20030101 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1741-7015 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0025774 issn: 1741-7015 databaseCode: DIK dateStart: 20030101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1741-7015 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0025774 issn: 1741-7015 databaseCode: GX1 dateStart: 20030101 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources (selected full-text only) customDbUrl: eissn: 1741-7015 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0025774 issn: 1741-7015 databaseCode: M~E dateStart: 20030101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1741-7015 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0025774 issn: 1741-7015 databaseCode: RPM dateStart: 20030101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1741-7015 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0025774 issn: 1741-7015 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1741-7015 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0025774 issn: 1741-7015 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 1741-7015 dateEnd: 20250131 omitProxy: true ssIdentifier: ssj0025774 issn: 1741-7015 databaseCode: M48 dateStart: 20031101 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal – providerCode: PRVAVX databaseName: HAS SpringerNature Open Access 2022 customDbUrl: eissn: 1741-7015 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0025774 issn: 1741-7015 databaseCode: AAJSJ dateStart: 20031201 isFulltext: true titleUrlDefault: https://www.springernature.com providerName: Springer Nature – providerCode: PRVAVX databaseName: Springer Nature OA Free Journals (Selected full-text) customDbUrl: eissn: 1741-7015 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0025774 issn: 1741-7015 databaseCode: C6C dateStart: 20031201 isFulltext: true titleUrlDefault: http://www.springeropen.com/ providerName: Springer Nature |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1ba9swFBZbC2MvY_d56zINBnvYRG1ZluWn0YSWMkgZpYWwFyHLUhPo7C4X6M_fObKdzB3riyHRMVg6t0_SuRDyyXifxh77u6TGMVEZwQz3nIG1LKqYF0JYPO-YnsnTS_F9ls26A7dVF1bZ28RgqKvG4hn5Ice8NpkCnv9285th1yi8Xe1aaDwk-wlAFZTqfLbbcGWAbfpEGSUPV-DbEgy5FSxOQZbZ7cAZhZr9_1rmv1zT3bDJO3enwSWdPCVPOixJj1rmPyMPXP2cPJp2t-UviL-YL5tfZYNRsOCiaEJdPUcur2hbwHlhKQgYyESbv0hNXdHuxoaCx3TY2A4oqLGbtWNNzWxbSpdeYzQH9WaBQe0vyeXJ8cXklHV9FZgFPLJmtuReFN7LIqt4alVaOXDr3NtE-MQA7xwv0Ut55UWuTGkdYAxRCCcSYRMwEa_IXt3U7g2hgN5ib1NZZRwLzRklPRqNxLnUS6VERJJ-gbXtio5j74trHTYfSuqWKRqYogNT9G1EvmzfuWlLbtxLPUa-bSmxXHb4o1le6U77dAwSWUhjc26NsNaWviryMpfGJ6UqLXzmB-S6bnNPt0qvj3JAM7GALWtEPgcKVHuYgDVd9gIsAxbQGlAeDChBXe1wuJcs3ZmLld4Jd0Q-bofxTQyBq12zQZo0z-MM4FhEXreCuJ10qgBXAvKLiBqI6GBVhiP1Yh6KiYfCsELFEfnaS_Puu_6_7G_vn8Y78pi3esbi7IDsrZcb9x7Q27ocBRUdkf3x8dmPc_g1kZNROAmB51QoeJ6Pf_4BT1RH2g |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkYAL4k2gUCOBOIDVxHYS54BQeVRb2u1pK-3NOI7NrtQm7T5E-VP8Rmby2CVF9NZrPIlsz9PxzDeEvDbei9BjfxdhHJOFkcxwzxlYy6wIeSalxf8dw6NkcCy_jePxBvnd1cJgWmVnE2tDXVQW_5HvcKxrSwTE8x_Pzhl2jcLb1a6FRiMWB-7XTziyzT_sfwH-vuF87-vo84C1XQWYBW-8YDbnXmbeJ1lccGGVKBw4Ne5tJH1kYOaO52ijvfIyVSa3DjyszKSTkbQRKAh89wa5KUUoEas_Ha8PeDHEUl1hjkp25uBLI0zxlSwUoDvsouf86h4B_3qCv1zh5TTNS3e1tQvcu0futrEr3W2E7T7ZcOUDcmvY3s4_JH40mVWneYVZt-ASaURdOUGpmtMGMHpqKQg0yGBTL0lNWdD2hoiCh3bYSA8oqLHLhWNVyWwD3UtPMHuEejPFJPpH5Phadvwx2Syr0j0lFKLF0FuRFDFHYDujEo9GKnJO-EQpGZCo22BtW5Bz7LVxouvDjkp0wxQNTNE1U_RFQN6t3jlrID6upP6EfFtRIjx3_aCa_dCttusQNCBLjE25NdJam_siS_M0MT7KVW5hmtvIdd3Uuq6MjN5NIXoKJRyRA_K2pkAzAwuwpq2WgG1AwK4e5VaPEsyD7Q93kqVb8zTXa2UKyKvVML6JKXelq5ZII9I0jCH8C8iTRhBXixYK4liINAOieiLa25X-SDmd1ODlNRCtVGFA3nfSvJ7X_7f92dXL2Ca3B6PhoT7cPzp4Tu7wRudYGG-RzcVs6V5A5LjIX9bqSsn367YPfwCZZn8_ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1La9wwEBYlgdBL6btu00aFQg-tiC3LsnzcPpZ024RCE8hNyLKUXUjtsOuF_vzOWLYbpw_o1RqBrXl9smY-EfLKeJ_GHu93SY1jojKCGe45g2hZVDEvhLD4v-P4RB6dicV5dn6ti7-rdh-OJENPA7I01e3hVeWDiyt5uIEslWDxrGBxClbJAEXuqqyQsP3anc0W3xbjpisDfDM0y_xx5iQhdbz9v0fna-npZunkjfPTLi3N75I7PZ6ks2AA98gtV98ne8f9ifkD4k-X6-Z72WAlLKQpmlBXL1HTGxpInFeWgpGBXYQeRmrqivanNhSypsPL7UCCGrttHWtqZgOdLr3Eig7qzQoL2x-Ss_nH0_dHrL9bgVnAJC2zJfei8F4WWcVTq9LKQWrn3ibCJwb053iJmcorL3JlSusAZ4hCOJEIm0CYeER26qZ2TwgFBBd7m8oq40g2Z5T0GDgS51IvlRIRSYYF1rYnHsf7Ly51twFRUgelaFCK7pSif0TkzTjnKtBu_FP6HeptlETK7O5Bs77QvQfqGKyykMbm3BphrS19VeRlLo1PSlVaeM0D1LoO_aej4-tZDogmFrBtjcjrTgJdHz7Amr6DAZYBSbQmkvsTSXBZOx0eLEv3IWOjOTZuyhQ2rBF5OQ7jTCyDq12zRZk0z-MMIFlEHgdDHD86VYAtAf1FRE1MdLIq05F6tewIxTtyWKHiiLwdrPnXe_192Z_-n_gB2fv6Ya6_fDr5_Izc5sEFWZztk512vXXPAdy15Yvef38CttdIbA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Thrombospondin+1+enhances+systemic+inflammation+and+disease+severity+in+acute-on-chronic+liver+failure&rft.jtitle=BMC+medicine&rft.au=Hozeifa+Mohamed+Hassan&rft.au=Liang%2C+Xi&rft.au=Jiaojiao+Xin&rft.au=Lu%2C+Yingyan&rft.date=2024-03-05&rft.pub=BioMed+Central&rft.eissn=1741-7015&rft.volume=22&rft.spage=1&rft_id=info:doi/10.1186%2Fs12916-024-03318-x |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1741-7015&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1741-7015&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1741-7015&client=summon |